Kenvue Inc. (KVUE) Fair Value & Analysis
Consumer Defensive · US · Market cap $36.5B · ISIN US49177J1025
What is Kenvue Inc. really worth?
Kenvue Inc.
KVUE · US
A solid business, but trading 73% above our fair value of $10.97.
Strengths
Risks
For context
Fair value as of: Sep 5, 2026
From 24 valuation models · updated today
Share price −3.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($18.15). The favourable scenario is already priced in.
- Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($8.51 to $18.15) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.
How to read this chart
40‑month range $13.61 – $24.34 · fair‑value band $8.51 – $18.15 · the $18.95 price screens above the $10.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.
Analysis
Kenvue Inc. (KVUE) currently trades at $18.95, while our model-based Fair Value estimate is $10.97, implying the stock looks roughly 72.7% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Consumer Defensive sector. Bull case: the Multiples group reads highest at a median of $13.02 per share, and 2 of the 24 models we run sit above the $18.95 price. Bear case: the Asset-Based group reads lowest at $3.76, and 22 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Kenvue Inc. generated revenue of $15.3B at a net margin of 10.6%. Revenue grew 4.5% year over year. It earns a return on equity of 15.7%. Net debt stands at $7.5B. Fundamentals as of Sep 5, 2026
Our scenario range runs from $8.51 (bear case) to $18.15 (bull case); at $18.95, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 40% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at −28% fair-value upside, at −42%, KVUE screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.0149 per share, which is 0.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Multiples ($13.02) versus Asset-Based ($3.76). Highest evidence: FCF DCF (78).
Notify me when KVUE reaches fair value
Put KVUE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 57
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health.
Full company description
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Kenvue Inc. reported revenue of $15.1B in FY2025 versus $15.1B in FY2021, a compound +0.1%/yr. Reported net income was $1.5B in FY2025, compounding −8.3%/yr from FY2021.
KVUE screens 73% overvalued. Compare with L'Oréal S.A →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Kimberly Clark (KMB) Names New Legal Chief As Kenvue Deal Puts Valuation In Focus
- Kenvue (KVUE) Stock Looks Cheap On Cash Flow But Fair On Earnings
- Should Zyrtec’s New Drug-Free Allergen Shield Spray Launch Require Action From Kenvue (KVUE) Investors?
Peer Group
Household & Personal Products · 244 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 30/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| L'Oréal S.A LORL | C$24.76 | C$22.64 | −9% |
| Unilever PLC UNA | €55.92 | €40.47 | −28% |
| Colgate-Palmolive Company CL | $90.75 | $55.28 | −39% |
| 500696 500696 | ₹2,093 | ₹641.55 | −69% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,015 | ₹789.46 | −61% |
| Kimberly-Clark Corporation KMB | $109.55 | $79.71 | −27% |
| Henkel AG HEN3 | €75.82 | €85.95 | +13% |
| The Estée Lauder Companies Inc ESLA | €86.54 | €18.84 | −78% |
| Church & Dwight Co CHD | $101.26 | $65.12 | −36% |
| Beiersdorf Aktiengesellschaft, BEI | €80.42 | €68.36 | −15% |
Compare Kenvue Inc. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Kenvue Inc. (KVUE) overvalued or undervalued?
What is the fair value of KVUE?
What is the quality score of KVUE?
What is the revenue of Kenvue Inc. (KVUE)?
What is the net profit margin of KVUE?
Does Kenvue Inc. pay a dividend?
Watch Kenvue Inc. in the live analysis
One click puts Kenvue Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.